

# 25th IRCMS Seminar

Date: **June 9, 2017 (Friday)**

Time: 16:00 - 17:00

Venue: 2F Seminar Room,  
Center for AIDS Research (CAIDS)

Speaker: **Eishu Hirata, M.D. Ph.D.**

Senior Assistant Professor  
Department of Oncologic Pathology,  
Kanazawa Medical University



Title: **Imaging 'Failure'**  
**How BRAF inhibition generates drug**  
**tolerant microenvironments**

Abstract:

Intravital imaging of BRAF-mutant melanoma cells containing an ERK/MAPK biosensor reveals how the tumor microenvironment affects response to BRAF inhibition by PLX4720. Initially, melanoma cells respond to PLX4720, but rapid reactivation of ERK/MAPK is observed in areas of high stromal density. This is linked to “paradoxical” activation of melanoma-associated fibroblasts by PLX4720 and the promotion of matrix production and remodeling leading to elevated integrin  $\beta$ 1/FAK/Src signaling in melanoma cells. Fibronectin-rich matrices with 3–12 kPa elastic modulus are sufficient to provide PLX4720 tolerance. Co-inhibition of BRAF and FAK abolished ERK reactivation and led to more effective control of BRAF-mutant melanoma. We propose that paradoxically activated MAFs provide a “safe haven” for melanoma cells to tolerate BRAF inhibition.

International Research Center for Medical Sciences (IRCMS)



TEL:096-373-6847 FAX:096-373-6869

ircms@jimu.kumamoto-u.ac.jp